“Global cannabidiol market accelerates, powered by soaring adoption in health, beauty, and functional wellness sectors, and a global shift toward natural, plant-based solutions.”
Lifescience
“Global cannabidiol market accelerates, powered by soaring adoption in health, beauty, and functional wellness sectors, and a global shift toward natural, plant-based solutions.”
Cannabidiol (CBD) is a form of phytocannabinoid that are extracted from cannabis plant. It has several characteristics properties such as anti-inflammatory and anti-inflammatory property which makes it ideal for seizure and chronic pain treatment. With the growing incidence of patients with chronic pain, there is surge in the demand for advanced drug formulation that aids in managing pain so patients can live a quality life. Notably, there is a rapid increase in the patients with neurological conditions including seizures and anxiety disorders. Being an anticonvulsant, cannabidiol is widely adopted for managing pain conditions and disease progression. In addition, cannabidiol is also used as a muscle relaxant and analgesic, which further increased its demand for therapeutic purposes. It is important to highlight here that, until 2023, the USFDA has approved medical cannabis-derived drug product, namely Epidiolex® for the treatment of seizures. Also, three synthetic medical cannabis-derived drug products, namely Cesamet™, Marinol® and Syndros® have been approved for the treatment of nausea which associated with cancer chemotherapy and anorexia, associated with weight loss in AIDS patients. In addition to therapeutic usage, these cannabidiol-based products, post cannabis testing, are currently being used to manufacture cannabis-infused drinks that promote relaxation and reduce anxiety. For instance, in January 2024, Aurora Cannabis launched three cannabis-infused ready-to-drink beverages. These cannabis-infused drinks are available in a variety of fruit flavors and are aimed to promote relaxation, pain alleviation and reduction of anxiety.
According to the research report "Global Cannabidiol Market Outlook, 2030," published by Bonafide Research, the Global Cannabidiol market was valued at more than USD 9.16 Billion in 2024, and expected to reach a market size of more than USD 21.48 Billion by 2030 with the CAGR of 15.59% from 2025-2030. cannabidiol oil is widely used as a key ingredient in making dermatological based products for treating wrinkles and acne. The increasing usage of cannabidiol based products across wide range of industrial verticals is catering attention of industry stakeholders widen their research on cannabidiol and drive new products. The key players, such as Aurora Cannabis, Medical Marijuana, and Medtera are focusing on the product portfolio expansion and leveraging partnerships for increasing bioavailability of cannabidiol. For instance, in January 2023, Medical Marijuana along with its subsidiary HempMeds Brasil launched two cannabidiol products, available in concentrations range from 3,000-6,000 mg, in Brazil. The market will remain competitive featuring several small, mid-sized and large industrial leaders who are currently active across different segments of industry. In addition to the pharmaceutical sector, the stakeholders are also emphasizing on sourcing cannabidiol for food & beverage industries, which is expected to be a key driver for the market. Moreover, the companies are also receiving a positive safety assessment of CBD food products by the regulatory authorities. In May 2024, Pureis® received the first, positive safety assessment for Ultra-Pure CBD product, a novel food supplement, from the UK Foods Standards Agency (FSA). This supports the company’s plan to receive the FSA approval in order to launch the product in the UK market.
Gummies and confectionery have emerged as the fastest-growing segment in the global cannabidiol (CBD) market due to their unique combination of convenience, taste, and versatility, which addresses several consumer preferences that other CBD products cannot fully satisfy. Unlike oils, tinctures, or capsules that may have an earthy or bitter flavor, gummies and confectionery provide a pleasant taste experience, making them more attractive to both new and existing CBD users. Gummies can be consumed anywhere, anytime, without the need for measuring drops or dealing with sublingual application, which can be inconvenient for some users. This makes them especially appealing for younger demographics, busy professionals, and wellness-conscious individuals who prefer simple, hassle-free methods of incorporating CBD into their daily routine. Dose consistency and safety further contribute to the popularity of gummies and confectionery. Each gummy or candy contains a pre-measured amount of CBD, ensuring accurate and predictable dosing, unlike oils or tinctures that require careful measurement. This precision appeals to consumers seeking reliable effects for relaxation, anxiety management, pain relief, or sleep improvement. Manufacturers often combine CBD with vitamins, minerals, adaptogens, or other wellness compounds to create multi-benefit products that appeal to health-conscious consumers. For example, CBD gummies may include ingredients to support sleep, energy, or immunity, positioning them not just as supplements but as part of a broader wellness lifestyle.
The pharmaceutical sector holds the largest share in the global cannabidiol market primarily due to its medical acceptance, clinical validation, and regulatory support. CBD is a non-psychoactive compound derived from cannabis plants, which has demonstrated significant therapeutic potential in treating a variety of conditions, including chronic pain, epilepsy, anxiety, sleep disorders, and neurodegenerative diseases. Prescription products containing CBD, particularly for the treatment of rare epileptic conditions, have been rigorously tested for safety, efficacy, and dosage control. This approval provides credibility and trust among healthcare professionals and patients alike, encouraging further adoption of CBD within medical practice. The pharmaceutical segment also benefits from growing research and clinical studies that explore CBD’s effectiveness in various therapeutic areas. Extensive studies on CBD’s anti-inflammatory, neuroprotective, and anxiolytic properties have expanded its application beyond epilepsy to include conditions such as chronic pain, multiple sclerosis, and anxiety disorders. As populations age and lifestyle-related health issues increase, there is a growing demand for safe and effective treatment options. CBD provides an alternative that is perceived as natural, well-tolerated, and non-addictive, which aligns with patient preferences for integrative and holistic healthcare solutions. Its application in pain management, mental health, and neurological therapy particularly drives pharmaceutical demand globally. The expansion of distribution channels in healthcare systems also supports this segment. Hospitals, specialty clinics, and pharmacies offer CBD-based medications, providing regulated and professional access.
E-commerce has emerged as the fastest-growing distribution channel in the global cannabidiol market due to its ability to address key consumer preferences for convenience, accessibility, and discretion. Unlike traditional retail stores, which may have limited shelf space and geographical reach, online platforms allow consumers to browse, compare, and purchase a wide range of CBD products from the comfort of their homes. A primary driver of e-commerce growth in the CBD market is consumer demand for privacy and discretion. Given that CBD is derived from cannabis plants, some buyers may feel hesitant or socially cautious about purchasing these products in physical stores. Online platforms provide a confidential shopping experience, allowing customers to explore product details, read reviews, and place orders without direct interaction with sales personnel. Another significant factor is the vast product variety and customization available online. E-commerce platforms often list products from multiple brands, including oils, tinctures, gummies, capsules, topicals, and even pet-focused CBD items. This extensive selection allows consumers to make informed choices based on price, potency, flavor, and form, which may not be possible in traditional retail outlets due to space constraints. Global accessibility is another major advantage. E-commerce enables CBD companies to reach consumers across regions and countries, bypassing the limitations of local distribution networks. This has become increasingly important as the global CBD market expands and regulations in multiple regions allow for the legal sale of low-THC products. Brands can leverage online channels to establish an international presence, introduce new products, and tap into emerging markets without the significant investment required for physical stores.
Marijuana has emerged as the fastest-growing source in the global cannabidiol market due to its high cannabidiol content, potent therapeutic potential, and increasing acceptance in medical and regulated recreational markets. Unlike hemp, which is cultivated primarily for industrial purposes and contains low tetrahydrocannabinol levels, marijuana plants can be selectively bred to produce higher concentrations of CBD alongside controlled THC levels. CBD derived from marijuana is used in clinical and prescription-grade products for conditions such as chronic pain, epilepsy, multiple sclerosis, and neurological disorders. The ability to produce higher CBD concentrations enables precise dosing and more effective treatment outcomes, which enhances its appeal in the pharmaceutical and therapeutic segments. The flexibility of marijuana strains also contributes to this segment’s accelerated growth. Cultivators can optimize cannabinoid profiles to balance CBD and THC levels, producing products tailored to specific consumer needs. For example, certain strains may target anxiety relief or sleep improvement without producing significant psychoactive effects. As medical cannabis policies become more permissive in several regions, marijuana-derived CBD has gained legal acceptance under strict controls. Regulated frameworks ensure product quality, safety, and standardization, which encourages both manufacturers and consumers to adopt marijuana as a reliable CBD source. In regions allowing recreational cannabis, marijuana-derived CBD also benefits from enhanced visibility and social acceptance, further driving market growth.
According to the research report "Global Cannabidiol Market Outlook, 2030," published by Bonafide Research, the Global Cannabidiol market was valued at more than USD 9.16 Billion in 2024, and expected to reach a market size of more than USD 21.48 Billion by 2030 with the CAGR of 15.59% from 2025-2030. cannabidiol oil is widely used as a key ingredient in making dermatological based products for treating wrinkles and acne. The increasing usage of cannabidiol based products across wide range of industrial verticals is catering attention of industry stakeholders widen their research on cannabidiol and drive new products. The key players, such as Aurora Cannabis, Medical Marijuana, and Medtera are focusing on the product portfolio expansion and leveraging partnerships for increasing bioavailability of cannabidiol. For instance, in January 2023, Medical Marijuana along with its subsidiary HempMeds Brasil launched two cannabidiol products, available in concentrations range from 3,000-6,000 mg, in Brazil. The market will remain competitive featuring several small, mid-sized and large industrial leaders who are currently active across different segments of industry. In addition to the pharmaceutical sector, the stakeholders are also emphasizing on sourcing cannabidiol for food & beverage industries, which is expected to be a key driver for the market. Moreover, the companies are also receiving a positive safety assessment of CBD food products by the regulatory authorities. In May 2024, Pureis® received the first, positive safety assessment for Ultra-Pure CBD product, a novel food supplement, from the UK Foods Standards Agency (FSA). This supports the company’s plan to receive the FSA approval in order to launch the product in the UK market.
Gummies and confectionery have emerged as the fastest-growing segment in the global cannabidiol (CBD) market due to their unique combination of convenience, taste, and versatility, which addresses several consumer preferences that other CBD products cannot fully satisfy. Unlike oils, tinctures, or capsules that may have an earthy or bitter flavor, gummies and confectionery provide a pleasant taste experience, making them more attractive to both new and existing CBD users. Gummies can be consumed anywhere, anytime, without the need for measuring drops or dealing with sublingual application, which can be inconvenient for some users. This makes them especially appealing for younger demographics, busy professionals, and wellness-conscious individuals who prefer simple, hassle-free methods of incorporating CBD into their daily routine. Dose consistency and safety further contribute to the popularity of gummies and confectionery. Each gummy or candy contains a pre-measured amount of CBD, ensuring accurate and predictable dosing, unlike oils or tinctures that require careful measurement. This precision appeals to consumers seeking reliable effects for relaxation, anxiety management, pain relief, or sleep improvement. Manufacturers often combine CBD with vitamins, minerals, adaptogens, or other wellness compounds to create multi-benefit products that appeal to health-conscious consumers. For example, CBD gummies may include ingredients to support sleep, energy, or immunity, positioning them not just as supplements but as part of a broader wellness lifestyle.
The pharmaceutical sector holds the largest share in the global cannabidiol market primarily due to its medical acceptance, clinical validation, and regulatory support. CBD is a non-psychoactive compound derived from cannabis plants, which has demonstrated significant therapeutic potential in treating a variety of conditions, including chronic pain, epilepsy, anxiety, sleep disorders, and neurodegenerative diseases. Prescription products containing CBD, particularly for the treatment of rare epileptic conditions, have been rigorously tested for safety, efficacy, and dosage control. This approval provides credibility and trust among healthcare professionals and patients alike, encouraging further adoption of CBD within medical practice. The pharmaceutical segment also benefits from growing research and clinical studies that explore CBD’s effectiveness in various therapeutic areas. Extensive studies on CBD’s anti-inflammatory, neuroprotective, and anxiolytic properties have expanded its application beyond epilepsy to include conditions such as chronic pain, multiple sclerosis, and anxiety disorders. As populations age and lifestyle-related health issues increase, there is a growing demand for safe and effective treatment options. CBD provides an alternative that is perceived as natural, well-tolerated, and non-addictive, which aligns with patient preferences for integrative and holistic healthcare solutions. Its application in pain management, mental health, and neurological therapy particularly drives pharmaceutical demand globally. The expansion of distribution channels in healthcare systems also supports this segment. Hospitals, specialty clinics, and pharmacies offer CBD-based medications, providing regulated and professional access.
E-commerce has emerged as the fastest-growing distribution channel in the global cannabidiol market due to its ability to address key consumer preferences for convenience, accessibility, and discretion. Unlike traditional retail stores, which may have limited shelf space and geographical reach, online platforms allow consumers to browse, compare, and purchase a wide range of CBD products from the comfort of their homes. A primary driver of e-commerce growth in the CBD market is consumer demand for privacy and discretion. Given that CBD is derived from cannabis plants, some buyers may feel hesitant or socially cautious about purchasing these products in physical stores. Online platforms provide a confidential shopping experience, allowing customers to explore product details, read reviews, and place orders without direct interaction with sales personnel. Another significant factor is the vast product variety and customization available online. E-commerce platforms often list products from multiple brands, including oils, tinctures, gummies, capsules, topicals, and even pet-focused CBD items. This extensive selection allows consumers to make informed choices based on price, potency, flavor, and form, which may not be possible in traditional retail outlets due to space constraints. Global accessibility is another major advantage. E-commerce enables CBD companies to reach consumers across regions and countries, bypassing the limitations of local distribution networks. This has become increasingly important as the global CBD market expands and regulations in multiple regions allow for the legal sale of low-THC products. Brands can leverage online channels to establish an international presence, introduce new products, and tap into emerging markets without the significant investment required for physical stores.
Marijuana has emerged as the fastest-growing source in the global cannabidiol market due to its high cannabidiol content, potent therapeutic potential, and increasing acceptance in medical and regulated recreational markets. Unlike hemp, which is cultivated primarily for industrial purposes and contains low tetrahydrocannabinol levels, marijuana plants can be selectively bred to produce higher concentrations of CBD alongside controlled THC levels. CBD derived from marijuana is used in clinical and prescription-grade products for conditions such as chronic pain, epilepsy, multiple sclerosis, and neurological disorders. The ability to produce higher CBD concentrations enables precise dosing and more effective treatment outcomes, which enhances its appeal in the pharmaceutical and therapeutic segments. The flexibility of marijuana strains also contributes to this segment’s accelerated growth. Cultivators can optimize cannabinoid profiles to balance CBD and THC levels, producing products tailored to specific consumer needs. For example, certain strains may target anxiety relief or sleep improvement without producing significant psychoactive effects. As medical cannabis policies become more permissive in several regions, marijuana-derived CBD has gained legal acceptance under strict controls. Regulated frameworks ensure product quality, safety, and standardization, which encourages both manufacturers and consumers to adopt marijuana as a reliable CBD source. In regions allowing recreational cannabis, marijuana-derived CBD also benefits from enhanced visibility and social acceptance, further driving market growth.
Related Press Releases
Quick Contacts
Trusted Partners
Latest Press Release
We are friendly and approachable, give us a call.